Phase 1 · NCT04143802
A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943 in Patients With Type 2 Diabetes Mellitus
CompletedVerified
Registry record
Trial details
- Trial
- A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)
- ClinicalTrials.gov ID
- NCT04143802
- Indication
- Diabetes Mellitus, Type 2
- Phase
- Phase 1
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 72
- Status
- Completed
- Interventions
- Drug: LY3437943; Drug: Dulaglutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 20 Years – 70 Years
- Locations
- 4 sites · United States
- Study start
- 18 Dec 2019
- Primary completion
- 28 Dec 2020
- Study completion
- 28 Dec 2020
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 20 Jan 2021
Endpoints
Primary
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Secondary
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve of LY3437943; PK: Maximum Concentration (Cmax) of LY3437943; Change from Baseline in Mean Daily Plasma Glucose (PG)